Runx2 is required for the proliferation of osteoblast progenitors and induces proliferation by regulating Fgfr2 and Fgfr3 by Kawane Tetsuya et al.
1SCieNTifiC RepoRts |  (2018) 8:13551  | DOI:10.1038/s41598-018-31853-0
www.nature.com/scientificreports
Runx2 is required for the 
proliferation of osteoblast 
progenitors and induces 
proliferation by regulating Fgfr2 
and Fgfr3
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Runx2 and Sp7 are essential transcription factors for osteoblast differentiation. However, the molecular 
mechanisms responsible for the proliferation of osteoblast progenitors remain unclear. The early onset 
of Runx2 expression caused limb defects through the Fgfr1–3 regulation by Runx2. To investigate 
the physiological role of Runx2 in the regulation of Fgfr1–3, we compared osteoblast progenitors in 
Sp7−/− and Runx2−/− mice. Osteoblast progenitors accumulated and actively proliferated in calvariae 
and mandibles of Sp7−/− but not of Runx2−/− mice, and the number of osteoblast progenitors and their 
proliferation were dependent on the gene dosage of Runx2 in Sp7−/− background. The expression of 
Fgfr2 and Fgfr3, which were responsible for the proliferation of osteoblast progenitors, was severely 
reduced in Runx2−/− but not in Sp7−/− calvariae. Runx2 directly regulated Fgfr2 and Fgfr3, increased 
the proliferation of osteoblast progenitors, and augmented the FGF2-induced proliferation. The 
proliferation of Sp7−/− osteoblast progenitors was enhanced and strongly augmented by FGF2, and 
Runx2 knockdown reduced the FGF2-induced proliferation. Fgfr inhibitor AZD4547 abrogated all of the 
enhanced proliferation. These results indicate that Runx2 is required for the proliferation of osteoblast 
progenitors and induces proliferation, at least partly, by regulating Fgfr2 and Fgfr3 expression.
Osteoblast differentiation is regulated by Runx2, Sp7, and canonical Wnt signaling1. Since Runx2 is expressed in 
Sp7-deficient (Sp7−/−) mice and Ctnnb1 conditional knockout mice, Runx2 is the furthest upstream transcription 
factor in the regulation of osteoblast differentiation, and Runx2, Sp7, and canonical Wnt signaling are mutu-
ally regulated and maintain their expression1,2. Both osteoblast differentiation and the expansion of osteoblast 
progenitors are essential for bone development and bone regeneration. Although the mechanism for osteoblast 
differentiation has been well studied, the mechanism for the proliferation of osteoblast progenitors remains to be 
clarified1.
Many in vitro studies of Runx2 in the proliferation of osteoblastic cells has been reported. The proliferation 
of Runx2−/− calvarial cells was greater than that of wild-type calvarial cells; Runx2 induces G1 cell-cycle arrest 
through the induction of p27KIP1 in osteosarcoma cells; Runx2 expression is up-regulated in the cessation of cell 
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proliferation and down-regulated to minimal levels during the early S phase and mitosis in MC3T3-E1 preoste-
oblastic cells; Runx2 suppresses the proliferation of cells with osteogenic potential and osteosarcoma cells, and 
the introduction of siRNA against Runx2 into human mesenchymal stem cells increases proliferation3–7. Thus, all 
previous reports show that Runx2 inhibits the proliferation of osteoblastic cells in vitro.
Four fibroblast growth factor receptor (Fgfr) genes have been identified in mammals (Fgfr1 to Fgfr4). The 
affinity and specificity of Fgfr1–3 are regulated by tissue-specific alternative splicing, which occurs in the region 
encoding the carboxyl-terminal half of Ig domain III creating the different isoforms, IIIb and IIIc8. Fgf2, Fgf4, 
Fgf9, Fgf18, Fgfr1, Fgfr2, and Fgfr3 are expressed in mesenchymal cells in the calvaria9–16. The importance of 
FGF signaling in human skull development has been revealed by the identification of gain-of-function mutations 
in the FGFR1, FGFR2, and FGFR3 genes in a number of craniosynostosis syndromes, such as Apert, Crouzon, 
Pfeiffer, and Muenke syndromes and Thanatophoric dysplasia17. Fgf10, Fgfr1c, and Fgfr2c, which are expressed 
in mesenchyme, and Fgf8, Fgf4, and Fgfr2b, which are expressed in ectoderm, form an epithelial-mesenchymal 
interaction loop during the proximodistal and anteroposterior patterning of the limb bud18,19, and craniosynos-
tosis is accompanied by limb defects in Apert and Pfeiffer syndromes17.
FGF signals trigger a number of responses in target cells, including stemness, proliferation, anti-apoptosis, 
drug resistance, angiogenesis, epithelial-to-mesenchymal transition, and invasion, through RAS-MAPK, 
PI3K-AKT, PLCγ and DAG, and PLCγ and IP3. Furthermore, the FGF signaling pathway has crosstalk with the 
canonical Wnt signaling cascade. In cell proliferation, FGF signaling plays important roles through RAS-MAPK, 
PI3K-AKT, and canonical Wnt signaling20,21. Genomic alterations in FGFRs are associated with various cancers, 
including breast cancer, lung cancer, gastric cancer, multiple myeloma, myeloproliferative syndrome, rhabdomyo-
sarcoma, peripheral T-cell lymphoma, uterine tumors, and bladder tumors20,21.
We previously reported that Runx2 transgenic mice under the control of the Prrx1 promoter, which directs 
transgene expression to the limb bud mesenchyme and cranial mesenchyme from embryonic day (E) 9.522, 
exhibit craniosynostosis, ectopic bone formation, and limb defects23. Since FGF signaling plays an important role 
in limb development, we examined the involvement of Runx2 in the FGF signaling pathway in this study. Runx2 
directly regulated the Fgfr1, Fgfr2, and Fgfr3 genes. In order to elucidate the physiological role of Runx2 in the 
regulation of Fgfr1–3 expression, we further examined the proliferation of osteoblast progenitors. We found that 
Runx2 was required for the proliferation of osteoblast progenitors, and also that it induced proliferation, at least 
in part, through the regulation of Fgfr2 and Fgfr3.
Results
Defects in Fgf signaling for limb development in Tg(Prrx1-Runx2) mice. We previously reported 
that the early onset of Runx2 expression causes craniosynostosis, ectopic bone formation, and limb defects, and 
also that the severity of limb defects depends on the expression levels of the transgene23. An epithelial-mesen-
chymal interaction loop formed by Fgfs and Fgfrs is essential for limb development. Fgf10, which first appears 
in the mesenchyme, has affinity for Fgfr2b in the apical ectodermal ridge (AER), which is a thickening of the 
ectoderm at the apex of the developing limb bud and is formed along the border of dorsal and ventral ectoderm, 
and induces Fgf8 and Fgf4 in the AER. Fgf8 and Fgf4 have affinity for Fgfr1c and Fgfr2c expressed in the mesen-
chyme, and promote mesenchymal proliferation and the outgrowth of limb buds10,24–32. The Fgf8 and Fgf4, which 
are expressed in AER, and Shh, which is expressed in the zone of polarizing activity (ZPA), mutually support the 
expression33–35. In order to elucidate the mechanisms responsible for limb defects, we examined the expression of 
Fgf10 at E10.0 and that of Fgf8, Fgf4, and Shh at E10.5 in Tg(Prrx1-EGFP-Runx2) mice with high expression levels 
using whole mount in situ hybridization (Fig. 1A–H). Since Tg(Prrx1-EGFP-Runx2) mice were lethal at birth, we 
analyzed F0 littermates of wild-type and Tg(Prrx1-EGFP-Runx2) mice in each whole mount in situ hybridization. 
Therefore, the severity of the defect in limb development was different among F0 Tg(Prrx1-EGFP-Runx2) mice 
depending on the expression level of the transgene as previously described23. Fgf10 mRNA was detected in wild-
type and Tg(Prrx1-EGFP-Runx2) mice, while Fgf8, Fgf4, and Shh mRNA was detected in wild-type mice, but not 
in Tg(Prrx1-EGFP-Runx2) mice. In histological analyses, the AER was observed in the limb buds of wild-type 
mice, but was not apparent in Tg(Prrx1-EGFP-Runx2) mice at E10.5 (Fig. 1I,J). The endogenous Runx2 protein 
was undetectable in wild-type mice, while the Runx2 protein was present in mesenchymal cells, but not in the 
epithelium of the limb buds of Tg(Prrx1-EGFP-Runx2) mice (Fig. 1K,L). Fgf8 mRNA was detected in the AER 
of the limb buds of wild-type mice, but not in Tg(Prrx1-EGFP-Runx2) mice (Fig. 1M,N), and the number of 
TUNEL-positive cells was higher in the presumptive AER region of Tg(Prrx1-EGFP-Runx2) mice than in the AER 
of the limbs of wild-type mice (Fig. 1O,P). Enhanced apoptosis in the AER region was also observed in Fgf4 and 
Fgf8 double mutant mice32. Therefore, these results suggest that FGF10, which was expressed in mesenchymal 
cells, failed to induce Fgf8 and Fgf4 mRNA expression in the ectoderm, leading to the apoptosis of cells in the 
AER region of Tg(Prrx1-EGFP -Runx2) mice with high expression levels. Thus, ectopic expression of Runx2 in 
limb bud mesenchyme disturbed the induction of Fgf8 and Fgf4 expression in ectoderm by Fgf10 produced in 
mesenchyme.
Runx2 regulates the expression of Fgfr1, Fgfr2, and Fgfr3. Since Fgf10 mRNA was detected in mes-
enchymal cells, whereas Fgf8 and Fgf4 mRNA was not observed in the epithelium in Tg(Prrx1-EGFP-Runx2) 
mice, the expression of Fgfrs or their isoforms might have been disturbed in Tg(Prrx1-EGFP-Runx2) mice. 
Therefore, we examined the expression of Fgfr1–3 and their isoforms by real-time RT-PCR using RNA from 
EGFP-positive cells sorted from the cell suspensions of Tg(Prrx1-EGFP) mice and Tg(Prrx1-EGFP-Runx2) 
mice at E10.5 (Fig. 2). Fgfr1b, Fgfr1c, Fgfr2c, Fgfr3b, and Fgfr3c mRNA levels were significantly higher in 
Tg(Prrx1-EGFP-Runx2) mice than in Tg(Prrx1-EGFP) mice. The Runx2 expression in Tg(Prrx1-EGFP-Runx2) 
mice was 16 times higher than that in Tg(Prrx1-EGFP) mice in the microarray analysis using the sorted 
EGFP-positive cells (data not shown). Since Runx2 expression was not detected in wild-type limb buds (Fig. 1K), 
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the regulation of Fgfrs at this developmental stage is not a physiological function of Runx2. Therefore, we exam-
ined whether Runx2 induces the expression of Fgfr1–3 in osteoblast progenitors prepared from wild-type calvar-
ial cells as described in the Materials and methods (Fig. 3A). Infection with type II Runx2-expressing adenovirus 
induced Fgfr1, Fgfr2, and Fgfr3 mRNA and their IIIb and IIIc isoform mRNA. Since the induction of Fgfr2 by 
Runx2 in osteoblast progenitors was more apparent than that in limb bud mesenchymal cells at E10.5 (Figs 2 and 
3A), it is likely that the transcription factors and/or co-factors collaborating with Runx2 for Fgfr2 expression is 
more abundant in osteoblast progenitors than limb bud mesenchymal cells at E10.5. Further, the expression of 
the molecules related to alternative splicing may be also different, because Fgfr2b expression was not significantly 
upregulated in limb bud mesenchymal cells at E10.5 (Fig. 2). The induction of Fgfr1, Fgfr2, Fgfr3, and Fgfr4 
mRNA by Runx2 has also been reported by microarray analysis using RNA from immortalized Runx2−/− cal-
varial cells infected with Runx2-expressing adenovirus36. The introduction of Runx2 siRNA in osteoblast pro-
genitors reduced the expression of Fgfr2 and Fgfr3 (Fig. 3B). However, Runx2 siRNA reduced Runx3 mRNA as 
well as Runx2 mRNA, although the siRNA sequence was specific for Runx2. Therefore, we examined whether 
Runx2 regulates Runx3 expression (Supplemental Fig. 1). Runx3, but not Runx1 expression was markedly weaker 
in Runx2−/− calvariae than in wild-type and Sp7−/− calvariae (Supplemental Fig. 1A). The overexpression of 
Runx2 induced the expression of Runx3, but not that of Runx1 in wild-type osteoblast progenitors (Supplemental 
Fig. 1B). The overexpression of Runx3 induced neither Runx1 nor Runx2. Furthermore, the overexpression of 
Runx3 failed to induce Fgfr1, Fgfr2, and Fgfr3 (Supplemental Fig. 1B). These results indicated that Runx2, but not 
Runx3 regulates Fgfr1, Fgfr2, and Fgfr3.
Figure 1. Limb development in Tg(Prrx1-EGFP-Runx2) mice (A–H) Whole mount in situ hybridization. 
Whole mount in situ hybridization of the forelimb buds of wild-type mice (wt) (A,C,E,G) and Tg(Prrx1-EGFP-
Runx2) mice with strong expression (Tg) (B,D,F,H) at E10.0 (A,B) and E10.5 (C–H) using Fgf10 (A,B), Fgf8 
(C,D), Fgf4 (E,F), and Shh (G,H) probes. (I–P) Histological analysis. A histological analysis of the forelimb 
buds of a wild-type mouse (wt) (I,K,M,O) and Tg(Prrx1-EGFP-Runx2) (Tg) mouse with strong expression (Tg) 
(J,L,N,P) at E10.5. (I,J) H-E staining. The AER is observed in the wild-type mouse (I, arrowhead), but not in the 
Tg(Prrx1-EGFP-Runx2) mouse (J). D, dorsal; V, ventral. (K,L) Immunohistochemical analysis of Runx2 protein 
expression. The boxed region in L is amplified in the window. (M,N) In situ hybridization using the Fgf8 probe. 
(O,P) TUNEL staining. F0 littermates of wild-type and Tg(Prrx1-EGFP-Runx2) mice were compared in each 
whole mount in situ hybridization and histological analysis. Scale bars: 20 μm (A,B); 200 μm (C–H); 200 μm 
(I–P); 20 μm (inset in L).
www.nature.com/scientificreports/
4SCieNTifiC RepoRts |  (2018) 8:13551  | DOI:10.1038/s41598-018-31853-0
Direct regulation of promoters of Fgfr1, Fgfr2, and Fgfr3 by Runx2. Since Runx2 induced the 
expression of Fgfr1, Fgfr2, and Fgfr3 in vivo and in vitro, we performed reporter assays using the promoter 
regions of Fgfr1, Fgfr2, and Fgfr3 (Fig. 4). In the reporter assay using a 10-kb fragment of the Fgfr1 promoter 
region, which contains eighteen consensus Runx2-binding motifs (TGPyGGPy), Runx2 strongly induced 
reporter activity (Fig. 4A). Serial deletions of the 10-kb fragment showed that the distal 4 kb is, in part, respon-
sible for Runx2-dependent transcriptional activation; however, further deletions augmented Runx2-dependent 
transcriptional activation, and Runx2 still activated the reporter activity of the 0.2-kb fragment. In the 0.2-kb 
fragment, there was one overlapping Ets1-binding site and two putative Runx-binding sites, which contained the 
core four nucleotides of the consensus Runx2-binding motifs, R1 and R2 (Fig. 4B). The mutation of R1, but not 
R2 completely abolished Runx2-dependent transcriptional activation (Fig. 4C). Since R1 and the Ets1-binding 
sites are closely located, Runx2 and Ets1 may co-operatively bind to and activate the Fgfr1 promoter, as previously 
described for the Spp1 promoter37. It was not possible to confirm this because the mutation of the Ets1-binding 
site completely abolished the basal activity of the promoter (Fig. 4C).
In the reporter assay using a 2.5-kb fragment of the Fgfr2 promoter region, which contains four consensus 
Runx2-binding sites, Runx2 induced reporter activity (Fig. 4D). Serial deletions of the 2.5-kb fragment showed 
that the distal 1.13 kb was, in part, responsible for Runx2-dependent transcriptional activation; however, Runx2 
maintained the ability to enhance the transcription of the reporter vector containing a 0.39-kb deletion frag-
ment (Fig. 4D). The 0.39-kb fragment contained one consensus Runx2-binding motif (R2) and three putative 
Figure 2. Real-time RT-PCR analyses of the expression of Fgfr1, Fgfr2, and Fgfr3 The expression of Fgfr1, 
Fgfr2, and Fgfr3 and their respective IIIb and IIIc isoform mRNA in Tg(Prrx1-EGFP) and Tg(Prrx1-EGFP-
Runx2) mice was measured by real-time RT-PCR in triplicate. EGFP-positive cells were collected from limb 
buds of more than 70 F0 EGFP-positive embryos each in Tg(Prrx1-EGFP-Runx2) mice and Tg(Prrx1-EGFP) 
mice at E10.5 by sorting EGFP-positive cells using FACS, the EGFP-positive cells obtained in each sorting were 
pooled, and mRNA was extracted from the pooled cells. We normalized values to that of Gapdh. Values in wild-
type mice were defined as 1, and the relative levels are shown. Data are the mean ± SD. *p < 0.05, **p < 0.01.
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Figure 3. (A) Induction of Fgfr1, Fgfr2, and Fgfr3 by Runx2 in vitro. RNA was extracted from wild-type 
osteoblast progenitors that had been infected with an adenovirus expressing type II Runx2 and EGFP or EGFP 
alone. Samples were harvested 12 and 24 hrs after infection. Values in cells infected with the EGFP-expressing 
adenovirus were defined as 1, and the relative levels are shown. Data are the mean ± SD of 4 wells. **p < 0.01. 
(B) Suppression of Fgfr1, Fgfr2, and Fgfr3 expression by Runx2 siRNA. Osteoblast progenitors were prepared 
from the calvariae of wild-type newborn mice, and transfected with Runx2 siRNA. RNA was extracted 48 hours 
after transfection, and real-time RT-PCR was performed. Values in siRNA for the control were defined as 1, 
and the relative levels are shown. Data are the mean ± SE of 3 wells. **p < 0.01. Similar results were obtained in 
three independent experiments and representative data are shown.
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Figure 4. Reporter and ChIP assays of Fgfr1, Fgfr2, and Fgfr3 promoters. (A–C) Reporter assays of the Fgfr1 
promoter. (A) Schematic diagrams of the reporter vectors of the Fgfr1 promoter and their luciferase (Luc) 
activities. (B) The nucleotide sequence containing putative Runx2-binding sites in the 0.2-kb fragment. Ets1-
binding sites are underlined and putative Runx2-binding sites (R1 and R2) are boxed. The mutated sequences 
are shown above the boxes and lines. (C) Reporter activities of the 0.2-kb construct (p0.2k r1) and the 0.2-kb 
constructs carrying a mutated R1, R2, or Ets1 site. (D–F) Reporter assays of the Fgfr2 promoter. (D) Schematic 
diagrams of the reporter vectors of the Fgfr2 promoter and their luciferase activities. (E) The nucleotide 
sequence containing putative Runx2-binding sites in the 0.39-kb fragment. The putative Runx2-binding sites 
(R1–4) are boxed, and the mutated sequences are shown above or below the boxes. (F) Reporter activities of the 
0.39-kb construct (p0.39k r2) and the 0.39-kb constructs carrying mutated R1, R2, R3, or R4. (G–I) Reporter 
assays of the Fgfr3 promoter. (G) Schematic diagrams of the reporter vectors of the Fgfr3 promoter and their 
luciferase activities. (H) The nucleotide sequence containing putative Runx2-binding sites in the 0.23-kb 
fragment. The putative Runx2-binding sites (R1, R2) are boxed, and the mutated sequences are shown above the 
boxes. (I) Reporter activities of the 0.23-kb construct (p0.23k r3) and the 0.23-kb constructs carrying mutated 
R1, R2, or R1 and R2. Vertical lines in the diagrams represent the positions of consensus Runx2-binding motifs 
(A,D,G), and arrows indicate reported transcription start sites (B,E,H). In all reporter assays, C3H10T1/2 
cells were transfected with an empty (open column) or Runx2-expressing (closed column) vector. Data are 
the mean ± SD of 4 wells. *p < 0.01 versus the control. Three independent experiments were performed and 
representative data are shown. (J) ChIP assays. DNA before (input) and after immunoprecipitation with a 
monoclonal anti-Runx2 antibody (Runx2) or mouse IgG (IgG) was amplified by PCR using primers that 
amplify the sequences of Fgfr1 (−88 ~+199), Fgfr2 (−83 ~+216), and Fgfr3 (−188 ~+178). Similar results were 
obtained in three independent experiments and representative data are shown.
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Runx2-binding sites consisting of the four core nucleotides of the consensus Runx2-binding sequences (R1, R3, 
R4) (Fig. 4E). The mutation of R3 abolished Runx2-dependent transcriptional activation (Fig. 4F).
In the reporter assay using an 8-kb fragment of the Fgfr3 promoter region, which contained fourteen con-
sensus Runx2-binding motifs, Runx2 strongly induced reporter activity (Fig. 4G). Serial deletions of the 8-kb 
fragment to the 2.6-kb fragment reduced Runx2-dependent transcriptional activation; however, further deletions 
to the 0.23-kb fragment augmented Runx2-dependent transcriptional activation. Thus, we focused on the 0.23-kb 
fragment, which contained two putative Runx2-binding sites, R1 and R2 (Fig. 4H). The mutation of either R1 or 
R2 partly reduced Runx2-dependent transcriptional activation, and the mutations of both R1 and R2 completely 
abolished Runx2-dependent transcriptional activation (Fig. 4I).
We then examined the binding of endogenous Runx2 in the promoter regions of Fgfr1, Fgfr2, and Fgfr3 by 
ChIP assays (Fig. 4J). The promoter regions of Fgfr1 (−88 ~+199), Fgfr2 (−83 ~+216), and Fgfr3 (−188 ~+178), 
which contained the putative Runx2-binding sites responsible for Runx2-dependent transcriptional activation, 
were amplified by PCR using DNA immunoprecipitated with the anti-Runx2 antibody, but not with IgG.
Accumulation of proliferating osteoblast progenitors, which express Runx2 and Fgfr2, in calva-
riae and mandibles in Sp7−/− mice, but not in Runx2−/− mice. Although Runx2 is expressed in mes-
enchymal cells in the maxilla, mandible, and perichondrium of the humerus in Sp7−/− mice, their differentiation 
into osteoblasts is completely blocked38. Since Runx2 regulated Fgfrs in osteoblast progenitors (Figs 3 and 4), we 
focused on mesenchymal cells in intramembranous bone regions, including calvariae and mandibles, in Sp7−/− 
mice in order to clarify the physiological roles of Fgfr gene regulation by Runx2. We compared the intramembra-
nous bone area including the calvariae and mandibles in wild-type, Sp7−/−, and Runx2−/− mice at E18.5 (Fig. 5). 
In wild-type mice, bone structures were established and osteoblasts strongly expressed Col1a1 (Fig. 5G,J,M,P). 
Although Sp7−/− mice and Runx2−/− mice both showed no bone structure, the layer of mesenchymal cells in the 
calvarial region in Sp7−/− mice was much thicker than that in Runx2−/− mice (Fig. 5G-I,S). The expression of 
Col1a1 in mesenchymal cells was weak in Sp7−/− mice and Runx2−/− mice, but stronger in Sp7−/− mice than in 
Runx2−/− mice, and the Col1a1-positive area in Sp7−/− mandibles was much larger than that in Runx2−/− man-
dibles (Fig. 5J–L,P–R,T). Therefore, mesenchymal cells, which are considered to be osteoblast progenitors, were 
accumulated in calvariae and mandibles of Sp7−/− mice but not of Runx2−/− mice.
In limb bone development in wild-type mice at E18.5, chondrocytes in epiphysis expressed Col2a1, and met-
aphysis and diaphysis were already replaced with bone and occupied by osteoblasts, which expressed Col1a1 
(Supplemental Fig. 2A,D,G,J,M,P). Sp7−/− mice completely lacked bone formation, and the limb skeletons were 
cartilaginous at E18.5 (Supplemental Fig. 2B,E), as previously described38. Chondrocytes were maturated in the 
diaphysis, in which Col2a1 expression was absent, in Sp7−/− mice (Supplemental Fig. 2H,K). Osteoblast pro-
genitors, which expressed Col1a1, were accumulated in the perichondrium of Sp7−/− mice and some of them 
differentiated into morphologically chondrogenic cells, which expressed both Col2a1 and Col1a1 (Supplemental 
Fig. 2H,K,N,Q). Although the limb skeletons were also cartilaginous in Runx2−/− mice at E18.5, chondrocyte 
maturation was inhibited and chondrocytes in the entire femurs expressed Col2a1 (Supplemental Fig. 2C,F,I,L), 
as previously described39,40. The accumulation of mesenchymal cells in the perichondrium was absent, and osteo-
blast progenitors, which expressed Col1a1, were few (Supplemental Fig. 2O,R). These findings indicate that Runx2 
is required for the expansion of osteoblast progenitors in the perichondrium of endochondral bones.
We then performed immunohistochemistry using the anti-Runx2 and anti-Fgfr2 antibodies to examine 
the expression of Runx2 and Fgfr2 in osteoblast progenitors in Sp7−/− mice. Runx2 and Fgfr2 were strongly 
detected in osteoblasts in wild-type mice and osteoblast progenitors in Sp7−/− mice, but undetectable in the 
mesenchymal cells in Runx2−/− mice, although Fgfr2 was detected in chondrocytes of Runx2−/− mice (Fig. 6A–I, 
M–R). Real-time RT-PCR and Western blot analyses showed that total Runx2 mRNA, type II Runx2 mRNA, and 
Runx2 protein are expressed at similar levels in wild-type and Sp7−/− mice, that type I Runx2 mRNA is expressed 
at slightly higher levels in Sp7−/− mice than wild-type mice, and that Sp7 mRNA levels are extremely low in 
Runx2−/− mice (Fig. 6V–X).
BrdU-positive osteoblasts or osteoblast progenitors were observed at similar frequencies in wild-type and 
Sp7−/− mice, whereas BrdU-positive cells were severely reduced in mesenchymal cells in the calvarial region and 
mandible of Runx2−/− mice (Fig. 6J–L,S–U,Y,Z). These results indicate that Runx2 is required for the proliferation 
of osteoblast progenitors and the expansion of osteoblast progenitors in Sp7−/− mice.
Runx2 enhances the proliferation of osteoblast progenitors through Fgf signaling path-
way. In order to investigate the functions of Fgfr1–3 in the proliferation of osteoblast progenitors, siRNA for 
Fgfr1, Fgfr2, or Fgfr3 was introduced by electroporation into wild-type osteoblast progenitors and cells were stim-
ulated with FGF2 (Fig. 7A,B). siRNA for Fgfr1 augmented FGF2-induced proliferation, while siRNAs for Fgfr2 
and Fgfr3 inhibited FGF2-induced proliferation. The FGF2 treatment or the transfection of Runx2-expression 
vector by electroporation increased the proliferation of wild-type osteoblast progenitors, and the transfection of 
Runx2-expression vector enhanced FGF2-induced proliferation. The treatment with AZD4547, which is a specific 
Fgfr tyrosine kinase inhibitor that inhibits Fgfr1–3, reduced the proliferation of wild-type osteoblast progenitors 
and abrogated increases by FGF2 and/or Runx2 (Fig. 7C).
The MAPK inhibitor, U0126, exerted similar effects to AZD4547, whereas the PI3K inhibitor, LY294002, and 
Akt inhibitor failed to inhibit proliferation and FGF2-induced proliferation of wild-type osteoblast progenitors 
(Fig. 7D). In accordance with these results, the treatment with FGF2 enhanced the phosphorylation of MAPK, 
and this phosphorylation was strongly inhibited by U0126 and AZD, whereas the treatment with FGF2 failed 
to enhance the phosphorylation of Akt (Fig. 7E,F). These results indicate that Fgfr signaling through Fgfr2 and 
Fgfr3 regulates the proliferation of osteoblast progenitors mainly through the MAPK pathway, and that Runx2 
enhances proliferation and FGF2-induced proliferation through the regulation of the Fgfr signaling pathway.
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Figure 5. Histological analysis of Sp7−/− and Runx2−/− mice Frontal sections of wild-type (wt) (A,D,G,J,M,P), 
Sp7−/− (B,E,H,K,N,Q), and Runx2−/− (C,F,I,L,O,R) mice at E18.5 were stained with H-E (A–C,G–I,M–O), or 
subjected to in situ hybridization using the Col1a1 probe (D–F,J–L,P–R). The boxed regions in A, B, and C are 
magnified in G and M, H and N, and I and O, respectively. The boxed regions in D, E, and F are magnified in J 
and P, K and Q, and L and R, respectively. Brackets in (G–L) indicate the layers of osteoblastic cells or osteoblast 
progenitors in the calvarial region. The widths of calvariae (wt: n = 8, Sp7−/−: n = 6, Runx2−/−: n = 5), and 
Col1a1-positive area in mandibles (wt: n = 4, Sp7−/−: n = 3, Runx2−/−: n = 3) were measured and shown in S and 
T, respectively. The values in wild-type mice were set as 1, and the relative levels are shown in T. Bars: 500 μm 
(A–F), 100 μm (G–L), 200 μm (M–R).
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Figure 6. Runx2 and Fgfr2 expression and BrdU labeling in the calvaria and mandible of wild-type, Sp7−/−, 
and Runx2−/− mice (A–U) Frontal sections of wild-type (A,D,G,J,M,P,S) and Sp7−/− (B,E,H,K,N,Q,T), and 
Runx2−/− (C,F,I,L,O,R,U) mice at E18.5 were reacted with the anti-Runx2 antibody (A–F,M–O) and anti-Fgfr2 
antibody (G–I,P–R) or subjected to BrdU labeling (J–L,S–U). The boxed regions in A are magnified in D and 
M, the boxed regions in B are magnified in E and N, and the boxed regions in C are magnified in F and O. The 
boxed regions in (D–F) and (M–O) are magnified in (D’–F’) and (M’–O’), respectively. The similar regions of 
(D’–F’) are shown in (G–I) and (J–L), and those of (M’–O’) are shown in (P–R) and (S–U). Brackets in (D’–L) 
indicate the layers of osteoblastic cells or osteoblast progenitors in the calvarial region, short arrows in (G–I) 
indicate muscle fibers, arrowheads in (G–I) and (P–R) indicate chondrocytes, and long arrows in R indicate 
neurons. Bars: 500 μm (A–C), 100 μm (D–F,M–O), 20 μm (D’-L, M’–U). (V) Real-time RT-PCR analysis. RNA 
was extracted from the calvariae of wild-type, Sp7−/−, and Runx2−/− mice at E18.5. The values in wild-type 
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Involvement of Runx2 in the enhancement of the proliferation of Sp7−/− osteoblast progen-
itors by FGF2. The proliferation of osteoblast progenitors from Sp7−/− calvaria was faster than wild-type 
osteoblast progenitors, enhanced proliferation by FGF2 was markedly stronger in Sp7−/− osteoblast progenitors 
than in wild-type osteoblast progenitors, and the treatment with AZD4547 abolished accelerated proliferation 
and enhanced FGF2-induced proliferation (Fig. 7G). The introduction of siRNA for Runx2 into Sp7−/− osteoblast 
progenitors reduced the expression of Ccnd1, Fgfr2, and Fgfr3 (Fig. 7H) as well as FGF2-induced proliferation 
(Fig. 7I).
We compared the expression of Fgfr1–3 in the calvariae of wild-type, Sp7−/−, and Runx2−/− mice using a drop-
let digital RT-PCR analysis, which detects the absolute number of each mRNA. The expression levels of Fgfr1–3 
were Fgfr1 > Fgfr2 > Fgfr3 in wild-type and Runx2−/− calvariae, and Fgfr1 = Fgfr2 > Fgfr3 in Sp7−/− calvariae 
(Fig. 8A). The expression of Fgfr4 was undetectable in wild-type calvariae (data not shown). Fgfr1, Fgfr2, and 
Fgfr3 mRNA levels were markedly lower in Runx2−/− calvariae than in wild-type and Sp7−/− calvariae. Although 
the level of Fgfr1 was lower in Sp7−/− calvariae than in wild-type calvariae, those of Fgfr2 and Fgfr3 were simi-
lar between wild-type and Sp7−/− calvariae (Fig. 8A). In the ChIP assay using Sp7−/− calvariae, Runx2-binding 
regions in Fgfr1, Fgfr2, and Fgfr3 were amplified by PCR in DNA precipitated with the anti-Runx2 antibody, but 
not with IgG (Fig. 8B). These results indicate that Runx2 also directly regulates the expression of Fgfr2 and Fgfr3 
in Sp7−/− calvariae and enhances the FGF2-induced proliferation of Sp7−/− osteoblast progenitors.
We also examined whether FGFs enhances the Runx2 capacity for transcriptional activation. Either FGF2 or 
FGF18 enhanced Runx2-dependent transcription in the reporter assays using the luciferase vector containing six 
tandem repeats of a Runx2 binding site (6XOSE2) (Supplemental Fig. 3).
Signaling pathways involved in the proliferation of osteoblast progenitors. To investigate 
other signaling pathways than Fgf involved in the proliferation of osteoblast progenitors, the expression of cell 
proliferation-related genes in calvarial tissues of Sp7−/− mice and Runx2−/− mice was compared by microarray 
(Supplemental Tables 1 and 2). The expression of the genes in Wnt (Wnt10b, Lef1), hedgehog (Ihh), and Phtlh 
(Pth1r, Pthlh) signaling pathways was increased more than two times in Sp7−/− calvarial tissues compared with 
Runx2−/− calvarial tissues. Therefore, the effects of FGF2, Wnt3a, Ihh, Shh, and PTHrP (1–34) on the proliferation 
of wild-type osteoblast progenitors, which were transfected with either GFP- or Runx2-expression vector, were 
compared. Runx2 induced proliferation, and FGF2 but not Wnt3a, Ihh, Shh, and PTHrP (1–34) increased the 
proliferation in either GFP- or Runx2-transfected cells (Fig. 8C).
Differential expression of the genes related to cell proliferation in Runx2−/− osteoblast pro-
genitors in vitro and in vivo. The proliferation of Runx2−/− osteoblast progenitors was increased 
in vitro as previously described (Fig. 8D)6. To clarify the reason for the discrepancy of the proliferation capacity 
of Runx2−/− osteoblast progenitors in vitro and in vivo, the expression of the cell proliferation-related genes in 
Runx2−/− osteoblast progenitors was compared with that in wild-type osteoblast progenitors in vitro, and that in 
Runx2−/− calvarial tissues was compared with that in wild-type calvarial tissues by cap analysis of gene expres-
sion (CAGE). And the genes, in which the expression ratios in vitro were more than two times or less than half 
compared with the expression ratios in vivo, were selected (Supplemental Tables 3 and 4). Many genes related to 
cell proliferation were differentially expressed in Runx2−/− osteoblast progenitors in vitro and in vivo. Further, the 
expression of Myc, Ccnd1, many growth factor genes, including Ereg, Hbegf, Tgfb1, Vegfa, Fgf7, Csf1, Fgf2, and 
Pdgfc, and a growth factor receptor gene Pth1r was upregulated in Runx2−/− osteoblast progenitors in vitro than 
in vivo. The differential expression of many cell proliferation-related genes in vitro and in vivo may explain why 
Runx2−/− osteoblast progenitors acquired augmented capacity for proliferation in vitro.
The proliferation of osteoblast progenitors in Sp7−/− mice is dependent on the gene dosage of 
Runx2. In order to investigate whether the proliferation of osteoblast progenitors in Sp7−/− mice is depend-
ent on Runx2, we generated Sp7−/−Runx2+/− mice and compared them with Sp7−/−Runx2+/+ mice (Fig. 9). 
The width of the layer of osteoblast progenitors in calvariae in Sp7−/−Runx2+/− mice was about half of that in 
Sp7−/−Runx2+/+ mice, and the number of BrdU-positive osteoblast progenitors in calvariae was markedly lower 
in Sp7−/−Runx2+/− mice than in Sp7−/−Runx2+/+ mice (Fig. 9K,L). The number of BrdU-positive osteoblast pro-
genitors in the mandible was also lower in Sp7−/−Runx2+/– mice than in Sp7−/−Runx2+/+ mice, but not by as much 
as that in calvariae (Fig. 9L,M). Interestingly, the tibiae and fibulae in Sp7−/−Runx2+/+ mice were severely bent 
due to the accumulation of osteoblast progenitors, whereas those in Sp7−/−Runx2+/– mice were not bent due to the 
reduction in the amount of osteoblast progenitors compared with Sp7−/−Runx2+/+ mice (Supplemental Fig. 4). 
These results indicate that the proliferation of osteoblast progenitors in Sp7−/− mice is dependent on the gene 
dosage of Runx2, and that the proliferation of osteoblast progenitors in calvariae is more dependent on the gene 
dosage of Runx2 than that in mandibles.
mice were set as 1, and relative levels are shown. Data are the mean ± SE of 4–5 mice. *vs. wild-type mice. 
*p < 0.05, **,††p < 0.01. (W) Western blot analysis. Protein was extracted from the calvariae of wild-type, 
Sp7+/−, and Sp7−/− mice at E18.5. β-actin was used as an internal control. (X) Quantification of Western blot 
bands. The normalized values of Runx2 protein bands in wild-type mice were set as 1, and the relative levels 
in Sp7−/− embryos are shown. Data are the mean ± SE of 3 bands. (Y and Z) BrdU-positive osteoblastic cells 
and osteoblast progenitors in calvariae (Y) and mandibles (Z) were counted and shown as a percentage of the 
number of osteoblastic cells and osteoblast progenitors. n = 6. **,††p < 0.01.
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Figure 7. Analyses of the proliferation of osteoblast progenitors in vitro (A) Reductions in Fgfr1, Fgfr2, and 
Fgfr3 mRNA by the introduction of respective siRNA into wild-type osteoblast progenitors. Each value of 
Fgfr1–3 in the introduction of control siRNA was set as 1 and the relative levels are shown. n = 3. **p < 0.01. 
(B) Effects of FGF2 and each siRNA for Fgfr1, Fgfr2, and Fgfr3 on the proliferation of wild-type osteoblast 
progenitors. The values of the vehicle in the control siRNA were set as 1, and the relative levels are shown. 
n = 4. * vs. the respective vehicle. †vs. the respective experiment in the control siRNA. **,††p < 0.01. (C) Effects 
of Runx2 on proliferation and the FGF2-induced proliferation of wild-type osteoblast progenitors and the 
inhibition by AZD4547 (50 nM). The values of the vehicle in the GFP group were set as 1, and the relative levels 
are shown. n = 4. * vs. the respective vehicle. †vs. the respective experiment in the GFP group. **,††,##p < 0.01. 
(D) Effects of inhibitors on the FGF2-induced proliferation of wild-type osteoblast progenitors. AZD: AZD4547 
(50 nM), U: U0126 (50 μM), LY: LY294002 (1 μM), Akt-I: Akt inhibitor (2.5 μM). The values in the vehicle were 
set as 1, and the relative levels are shown. n = 4. * vs. the respective vehicle. †vs. the respective experiment in 
the vehicle group. †p < 0.05, **,††p < 0.01. (E,F) Western blots of activated p42/44 MAP kinase (E) and Akt (F). 
IGF-1 was used as a positive control for Akt activation (F). (G) Effects of FGF2 and AZD4547 (50 nM) on the 
proliferation of Sp7−/− osteoblast progenitors. The values in the vehicle of wild-type osteoblast progenitors were 
set as 1, and relative levels are shown. n = 4. * vs. the respective vehicle. †vs. the respective experiment in the 
wild-type group. *,†,#p < 0.05, **,††,##p < 0.01. (H) Real time RT-PCR analysis using RNA from Sp7−/− osteoblast 
progenitors. The values for control siRNA were set as 1 and the relative levels are shown. n = 3. **p < 0.01. 
(I) The effects of siRNA for Runx2 on the FGF2-induced proliferation of Sp7−/− osteoblast progenitors. The 
values for the vehicle were set as 1 and the relative levels are shown. n = 4. * vs. the respective vehicle. †vs. 
the respective experiment in the control siRNA. **,††p < 0.01. Similar results were obtained in two to four 
independent experiments and representative data are shown in A–I.
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Discussion
Although Runx2−/− mice and Sp7−/− mice both completely lack osteoblasts and bone formation, osteoblast pro-
genitors, which abundantly expressed Runx2, accumulated and actively proliferated in the calvaria and mandible 
of Sp7−/− mice, and the number of osteoblast progenitors and their proliferation were dependent on the gene dos-
age of Runx2. Runx2 directly regulated Fgfr1–3 expression, enhanced the proliferation of osteoblast progenitors, 
and augmented the FGF2-induced proliferation through the Fgfr2/3-MAPK signaling pathway. Further, FGF2 
but not Wnt3a, Ihh, Shh, and PTHrP (1–34) increased the proliferation and augmented Runx2-induced prolifera-
tion. These results indicate that Runx2 is a requisite transcription factor not only for osteoblast differentiation but 
Figure 8. Droplet digital RT-PCR, ChIP, and cell proliferation analyses (A) Droplet digital RT-PCR analysis. 
The expression levels of Fgfr1–3 were compared among wild-type, Sp7−/−, and Runx2−/−calvariae. n = 4. *vs. 
wild-type mice. †vs. the respective mouse in Fgfr1. #vs. the respective mouse in Fgfr2. **,††,##p < 0.01. (B) ChIP 
assay. DNA was extracted from Sp7−/− calvariae, and DNA before (input) and after immunoprecipitation 
with the monoclonal anti-Runx2 antibody (Runx2) or mouse IgG (IgG) was amplified by PCR using the same 
primers as those in Fig. 4J. (C) The effects of FGF2, Wnt3a, Ihh, Shh, and PTHrP (1–34) in the proliferation of 
GFP- or Runx2-transfected wild-type osteoblast progenitors. n = 4. * vs. the vehicle in GFP-transfected cells. 
†vs. the vehicle in Runx2-transfected cells. *p < 0.05, **,††p < 0.01. (D) Proliferation of wild-type and Runx2−/− 
osteoblast progenitors. n = 4. **p < 0.01. Similar results were obtained in three independent experiments and 
representative data are shown in B-D.
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also for proliferation of osteoblast progenitors, and that Runx2 regulates the proliferation of osteoblast progeni-
tors, at least partly, through the induction of Fgfr2 and Fgfr3 expression.
Since FGF10 binds with high affinity to Fgfr1b and Fgfr2b41, limb defects were likely to have been caused 
by the up-regulated expression of Fgfr1b in the mesenchyme of the limb buds of Tg(Prrx1-EGFP-Runx2) mice 
(Figs 1 and 2), which will interrupt the translocation of Fgf10 to the ectoderm leading to the failure of the induc-
tion of Fgf8 and Fgf4 expression in the ectoderm. Limb defects in Pfeiffer and Apert syndromes are similar to 
those in Tg(Prrx1-EGFP-Runx2) mice with low expression levels17,23,42. FGF2 phosphorylates Runx2 through the 
MAPK pathway and enhances the transcriptional activity of Runx2, ERK-dependent phosphorylation stabilizes 
the Runx2 protein, and Runx2 is activated through the PI3K-Akt pathway43–46. We also confirmed that Runx2 
capacity for the transcriptional activation is enhanced by FGF2 and FGF18 (Supplemental Fig. 3). Since Runx2 
directly regulated the expression of Fgfr1–3, a positive feedback loop between FGFR signaling and RUNX2 may 
play an important role in the pathogenesis of craniosynostosis and limb defects caused by gain-of-function muta-
tions in FGFR1–3.
Runx2−/− calvaria-derived osteoblast progenitors proliferated faster than wild-type osteoblast progenitors in 
vitro (Fig. 8D), as previously reported6. However, the number of osteoblast progenitors in calvariae and mandibles 
of Runx2−/− mice was quite low, and the BrdU+ cells were severely reduced (Figs 5 and 6), indicating that there 
is a discrepancy in the proliferation of Runx2−/− osteoblast progenitors in vitro and in vivo. It was previously 
Figure 9. Comparison of the proliferation of osteoblast progenitors in Sp7−/−Runx2+/+ and Sp7−/−Runx2+/– 
mice (A–J) Frontal sections of Sp7−/−Runx2+/+ (A,C,E,G,I) and Sp7−/−Runx2+/– (B,D,F,H,J) mice at E18.5 were 
stained with H-E (A–D,G,H), or subjected to BrdU labeling (E,F,I,J). The upper boxed regions in A and B are 
magnified in C and D, and the lower boxed regions in A and B are magnified in G and H, respectively. Serial 
sections were used for BrdU labeling (E,F: calvarial region; I,J: mandibles). The brackets in (C–F) indicate the 
layers of osteoblast progenitors in the calvarial region. (K–M) The width of calvariae (K) and the percentage of 
BrdU-positive osteoblast progenitors in calvariae (L) and mandibles (M). The data are the mean ± SE of 3 mice. 
Bars: 500 μm (A,B), 200 μm (C–J).
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reported that the expression of Cdkn1a (p21CIP1) and Cdkn2a (p19ARF) is reduced in Runx2−/− osteoblast progen-
itors in vitro, and the introduction of Runx2 induces the expression of Cdkn1b (p27KIP1), Cdkn1a, and Cdkn2a, 
which prevent cell cycle progression through the inhibition of cyclin-dependent kinases (CDKs) or the stabiliza-
tion of p53 by inhibiting Mdm27,47. The report also showed that severe reduction of Cdkn1a and Cdkn2a expres-
sion in Runx2−/− osteoblast progenitors occurs after six passages of the cells47. We examined the proliferation 
and gene expression of Runx2−/− osteoblast progenitors after one passage of the cells, trying to mimic in vivo 
situation. Cdkn1b expression in Runx2−/− osteoblast progenitors was greater than that in wild-type osteoblast 
progenitors, Cdkn1a, Cdkn2a (p19ARF), and Cdkn2a (p16Ink4a) expression in Runx2−/− osteoblast progenitors was 
about 75% of wild-type osteoblast progenitors, and the introduction of Runx2 failed to induce their expression in 
vitro (Supplemental Table 5). Further, their expression ratios in Runx2−/− and wild-type osteoblast progenitors 
in vitro were much higher than those in Runx2−/− and wild-type calvarial tissues in vivo (Supplemental Table 5), 
indicating that the enhanced proliferation of Runx2−/− osteoblast progenitors in vitro cannot be explained by 
the expression levels of the CDK inhibitors. Since many genes related to cell proliferation were differentially 
expressed in Runx2−/− osteoblast progenitors in vitro and in vivo (Supplemental Table 3 and 4), it seemed to be 
difficult to reveal the function of Runx2 in the proliferation of osteoblast progenitors by investigating Runx2−/− 
osteoblast progenitors in vitro.
Reductions in the volume of osteoblast progenitors and their frequencies in BrdU uptake in the calvariae were 
greater than those in the mandibles in Sp7−/−Runx2+/– mice relative to the respective tissues in Sp7−/−Runx2+/+ 
mice (Fig. 9), indicating that osteoblast progenitor proliferation is more dependent on the gene dosage of Runx2 
in calvariae than mandibles. It may partly explain why open fontanelles and sutures are prominent phenotypes in 
cleidocranial dysplasia, which is caused by heterozygous mutation of RUNX248. High dependency on the amount 
of Runx2 protein among Runx family transcription factors in calvarial bone development is also shown in the com-
parison of Runx2+/– mice with conditional Cbfb knockout mice or Cbfb isoform knockout mice49,50. As osteoblast 
progenitors were scarce and the BrdU-positive cells were few in both regions of calvaria and mandible in Runx2−/− 
mice (Figs 5 and 6), however, our findings also indicate that Runx2 is required for the proliferation of osteoblast 
progenitors in both calvaria and mandible. During endochondral bone development, osteoblast differentiation 
occurs first in the perichondrium, and Sp7-expressing preosteoblasts invade the cartilage with blood vessels and 
give rise to trabecular osteoblasts51. The accumulation of osteoblast progenitors was observed in the perichon-
drium of cartilaginous limb skeletons of Sp7−/− mice but not in Runx2−/− mice, and the accumulation of osteoblast 
progenitors in Sp7−/− limb skeletons was also dependent on the gene dosage of Runx2 (Supplemental Figs 2 and 
4), indicating that Runx2 is also required for the proliferation of osteoblast progenitors for trabecular osteoblasts.
Runx2 is required for mammary gland development, and Runx2 deletion increased animal survival in a mouse 
model of breast cancer with reduced proliferation and cyclin D expression52. The strong expression of Runx2 is 
associated with estrogen receptor/progesterone receptor/HER2-negative breast cancer and patients with strong 
Runx2 expression have a poorer survival rate than those with negative or weak expression53. The FGFR2 gene 
has been identified as a locus associated with an increased risk of developing breast cancer, and a single nucle-
otide polymorphism in the FGFR2 gene, which enhances RUNX2 binding, increases FGFR2 expression54–57. 
Furthermore, the knockdown of RUNX2 reduced the expression of FGFR2 in the breast cancer cell line MCT-758. 
Since Runx2 directly regulated Fgfr2 and the knockdown of Fgfr2 was effective for inhibiting the proliferation of 
osteoblast progenitors, the regulation of FGFR2 by RUNX2 may also play an important role in the development 
and progression of some breast cancers by enhancing cell proliferation.
In conclusion, the comparison of Sp7−/− mice, Sp7−/−Runx2+/– mice, and Runx2−/− mice revealed the require-
ment of Runx2 in the proliferation of osteoblast progenitors. Runx2 regulated it, at least partly, through the reg-
ulation of Fgfr2 and Fgfr3. Since Fgf signaling enhances the ability of Runx2 for transcriptional activation, the 
reciprocal regulation of Runx2 and Fgf signaling will play important roles in skeletal development, the pathogen-
esis of craniosynostosis, and the progression of some breast cancers.
Materials and Methods
Generation of transgenic and gene-targeting mice. We generated Runx2 transgenic mice under the 
control of the Prrx1 promoter using enhanced green fluorescent protein (EGFP)-Runx2 fusion DNA {Tg(Prrx1-
EGFP-Runx2) mice}, EGFP transgenic mice under the control of the Prrx1 promoter {Tg(Prrx1-EGFP) mice}, 
and Runx2−/− mice as previously described23,59. In briefly, Prrx1 promoter- EGFP-Runx2 DNA fragment or Prrx1 
promoter-EGFP DNA fragment was injected into the pronuclei of fertilized eggs from C57BL/6 x C3H F1. As 
Tg(Prrx1-EGFP-Runx2) mice died at birth, we analyzed the F0 generation. The expression of transgenic embryos 
were screened by EGFP observation or real-time RT-PCR. Sp7−/− mice were generated as previously described60. 
Runx2+/– mice were backcrossed with C57BL/6 more than ten times. Sp7+/– mice were generated and maintained 
in C56BL/6 background. Prior to the study, all experiments were reviewed and approved by the Animal Care and 
Use Committee of Nagasaki University Graduate School of Biomedical Sciences (No. 1403111129-21). All animal 
experiments were performed in accordance with the law of humane treatment and management of animals in 
Japan, the standards for the breeding, maintenance and reducing pains of experimental animals by Ministry of 
the Environment in Japan, the basic guidelines of animal experiments by Ministry of Education, Culture, Sports, 
Science and Technology in Japan, and the rules for animal experiments in Nagasaki University.
Histological and immunohistochemical examinations. Tissues were fixed in 4% paraformalde-
hyde/0.1 M phosphate buffer and embedded in paraffin, and sections (thickness of 4 μm) were stained with 
hematoxylin and eosin (H-E). Immunohistochemical analyses were performed using a monoclonal anti-Runx2 
antibody (1:200 dilution; Medical & Biological Laboratories, Nagoya, Japan) and polyclonal rabbit anti-Fgfr2 
antibody (1:1000 dilution; GeneTex, Inc., Irvine, USA) as previously described61. Sections were counterstained 
with Methyl green. Immunohistochemistry without the anti-Runx2 antibody or anti-Fgfr2 antibody showed no 
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significant signals (data not shown). TUNEL staining was performed using the ApopTag® system (Intergen, 
Burlington, MA). For analysis of BrdU incorporation, we subcutaneously injected pregnant mice with 100 μg 
BrdU/g body weight 1 h before sacrifice. We processed the embryos for histological analysis and detected BrdU 
incorporation using BrdU staining kit (Invitrogen). The sections were counterstained with hematoxylin.
In situ hybridization. In in situ hybridization, single-stranded RNA probes labeled with digoxigenin-11-UTP 
were prepared using a DIG RNA labeling kit (Roche, Basel Switzerland) according to the manufacturer’s instructions. 
Sections were hybridized using mouse Fgf8 and Col1a1 antisense probes as described previously39. Whole mount in 
situ hybridization was performed using Fgf10, Fgf8, Fgf4, and Shh antisense probes as described previously62. The in 
situ hybridization of sections and whole embryos using sense probes showed no significant signals (data not shown).
Real-time RT-PCR. Real-time RT-PCR was performed using a THUNDERBIRD SYBR qPCR Mix (Toyobo) 
and Light Cycler 480 real-time PCR system (Roche Diagnostics). TaqMan PCR for Fgfr1, Fgfr2, Fgfr3, Runx1, 
Runx2, Runx3, and Sp7 was performed using a THUNDERBIRD Probe qPCR Mix (Toyobo). Primer sequences 
and information on TaqMan Probes are shown in Supplemental Table 6. We normalized values to that of β-actin.
Cell culture and adenoviral transfer. Wild-type, Sp7−/−, and Runx2−/− osteoblast progenitors 
were prepared from calvariae at E18.5. The calvariae were cut into small pieces and cultured for 10–14 days 
in three-dimensional collagen gel (Cell matrix, Nitta Gelatin, Co., Osaka, Japan) with α-modified Minimum 
(α-MEM) containing 10% FBS. The cells outgrowing from the explants were retrieved by incubation for 30 min 
with 0.2% collagenase (Wako Pure Chemical Industries, Osaka, Japan) in PBS(−) at 37 °C. In this method, the 
main cell types isolated were osteoblast progenitors and osteoblasts at an early differentiation stage with low 
alkaline phosphatase activity and virtually no osteocalcin production59. Cells were plated in 24-well plates at a 
density of 5 × 104/well in αMEM supplemented with 10% fetal bovine serum (FBS). At confluency, cells were 
infected with an adenovirus expressing EGFP or type II Runx2-EGFP at a multiplicity of infection of 10 for 2 hrs. 
The mouse pluripotent mesenchymal cell line, C3H10T1/2, was purchased from the RIKEN Cell Bank (Tsukuba, 
Japan), and cultured in BME supplemented with 10% FBS.
Reporter Assays. A 10-kb fragment of the Fgfr1 promoter region was subcloned into the firefly luciferase reporter 
vector pGL4.10Luc2 (Promega, Madison, WI) from the BAC clone. A 2.5-kb fragment of the Fgfr2 promoter region 
and 8-kb fragment of the Fgfr3 promoter region were amplified by PCR using mouse genomic DNA and cloned into 
pGL4.10Luc2. All truncated constructs were prepared using the restriction enzyme sites or by PCR amplification. 
C3H10T1/2 cells were transfected with plasmid DNAs (each luciferase reporter vector 0.1 μg; pRL-Tk Renilla 0.1 μg; 
pSG5 or pSG5-Runx2 0.05 μg) using FuGENE 6 Transfection Reagent (Roche). Luciferase activities were examined by 
using Dual-Luciferase Reporter Assay System (Promega), and normalized to Renilla luciferase activity.
ChIP assay. Chromatin immunoprecipitation (ChIP) was performed with a Chromatin Immunoprecipitation 
Assay Kit (Upstate Biotechnology, Billerica, MA) using the anti-Runx2 monoclonal antibody in Fig. 4J (Medical 
& Biological Laboratories), anti-Runx2 antibody in Fig. 8B (Santa Cruz Biotechnology, Santa Cruz, CA), or 
mouse IgG (Cell Signaling, Danvers, MA), using primers in Supplemental Table 6.
Western blot analysis. A Western blot analysis was performed using anti-Runx2 (Cell Signaling), rab-
bit anti-phospho-p44/42 MAPK (Thr202/Tyr204) (Cell Signaling), rabbit anti-phospho-Akt (ser473) (Cell 
Signaling), rabbit anti-p44/42 MAPK (Cell Signaling), rabbit anti-Akt (Cell Signaling), and anti-β-actin (Santa 
Cruz Biotechnology) antibodies.
Cell proliferation assay. A total of 5 × 105 cells were subjected to electroporation with 1.0 μg of either the 
EGFP or type II Runx2 expression vector or with 10 pmol of siRNA for Fgfr1, Fgfr2, Fgfr3 (Bonac, Kurume, 
Japan), or Runx2 (Thermo scientific, Waltham, MA) using the Neon Transfection System (Invitrogen) and cul-
tured on 100-mm dishes for 24 h, and then the transfected cells were seeded at 1 × 104 cells/well on 96-well plates. 
After 6 hrs, FGF2 (PeproTech Inc. Rocky Hill NJ), Wnt3a (R&D Systems, Minneapolis, MN), Ihh (R&D Systems), 
Shh (R&D Systems), or PTHrP(1–34) (PeproTech Inc.) was added. After 48 hrs, cell numbers were counted using 
Cell Counting Kit-8 (DOJINDO, Kumamoto, Japan). Inhibitors (AZD4547: Abcom, Cambridge, UK; U0126: 
Wako Pure Chemical Industries, Osaka, Japan; LY294002: Merck Calbiochem, Darmstadt, Germany; Akt inhib-
itor: Merck Calbiochem) were added 1 h before the addition of FGF2.
Droplet digital PCR. The absolute quantity of mRNA was measured by the QX200 Droplet Digital PCR 
System (BIO-RAD) using EvaGreen application reagents (BIO-RAD). The absolute values of mRNA were nor-
malized to those of β-actin mRNA.
Statistical analysis. Data are described as the mean ± SEM, if not specified. Statistical analyses were per-
formed using an analysis of variance followed by the Tukey-Kramer test. P < 0.05 was considered to be significant.
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